Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors

Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors

Abstract Oraxol consists of an oral dosage form of the chemotherapeutic agent paclitaxel administered with a novel P‐glycoprotein inhibitor encequidar methanesulfonate monohydrate (formerly named HM30181A), which allows oral treatment of cancers that would otherwise be treated with intravenous pacli...

Full description

Bibliographic Details
Main Authors: Jimmy He, Christopher G. C. A. Jackson, Sanjeev Deva, Tak Hung, Katriona Clarke, Eva Segelov, Tsu‐Yi Chao, Ming‐Shen Dai, Hsien‐Tang Yeh, Wen Wee Ma, Douglas Kramer, Wing‐Kai Chan, Rudolf Kwan, David Cutler, Jay Zhi
Format: Article
Language:English
Published: Wiley 2022-07-01
Series:CPT: Pharmacometrics & Systems Pharmacology
Online Access:https://doi.org/10.1002/psp4.12799

Internet

https://doi.org/10.1002/psp4.12799

Similar Items